Navigation Links
FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
Date:2/1/2012

s to recommend consideration of at least three years of adjuvant therapy with Gleevec for patients with high-risk GIST(2).

In addition to extending the Gleevec label to three-year treatment duration in patients with KIT+ GIST after surgery, the FDA has agreed that all accelerated post-approval commitments for this indication have been met, confirming the clinical benefit of adjuvant treatment with Gleevec.

Study details
The SSG XVIII clinical trial was conducted by the Scandinavian Sarcoma Group (SSG) and the Sarcoma Group of the Arbeitsgemeinschaft Internistische Onkologie (AIO). This trial was a multicenter, prospective, randomized study for the evaluation of adjuvant treatment with Gleevec of histologically confirmed KIT+ GIST(5).

The primary endpoint of the study was to compare, within the first five years, recurrence-free survival in patients with a greater than 50% estimated risk of GIST disease recurrence, following diagnosis and treatment with adjuvant Gleevec for either 12 or 36 months. The secondary endpoints included overall survival and treatment safety(1).

Three hundred ninety-seven patients entered the study. Inclusion criteria for risk of recurrence was defined as tumor diameter >5.0 cm and mitotic count >5/50 high power fields (HPFs); or tumor diameter >10.0 cm, any mitotic count; or tumor of any size with a mitotic count >10/50 HPFs; or tumors ruptured into the peritoneal cavity.

Recurrence-free survival was longer in the 36-month group compared to the 12-month group (HR 0.46, 95% CI 0.32-0.65; p<0.0001). Patients assigned to 36 months of Gleevec after surgery had longer overall survival (HR 0.45, 95% CI 0.22-0.89; p=0.0187). Almost all patients experienced side effects while taking Gleevec. Gleevec was generally well tolerated. The proportion of patients who discontinued Gleevec during the assigned treatment period for reasons other than GIST recurrence was 26% over the full three yea
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014  Mark Farrah Associates ... providing a summary of the 2015 marketplace exchange ... trends.  According to a recent ... and Evaluation, Department of Health and Human Services) ... in individual medical plans through the Marketplace as ...
(Date:12/22/2014)... 22, 2014 TWi Biotechnology, Inc., today ... for AC-201, TWi Biotechnology,s lead drug candidate, from ... China for patent application numbered 201180018154.8.  ... salts, active metabolite for treatment of type II ... treatment using AC-201 for type II diabetes, and ...
(Date:12/19/2014)... 19, 2014 You,re visiting the dentist for ... when he or she says you need a root ... you may have several questions and feel apprehensive about ... know it,s nothing to worry about. The Pennsylvania Dental ... alleviate any anxiety the public may have surrounding this ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Root Canals Have Become More Routine 2
... 22, 2011  PTC Therapeutics, Inc. (PTC) today announced ... Discovery (SDD) Award from the Wellcome Trust to ... life-threatening infections caused by multidrug-resistant (MDR) Gram-negative bacteria. ... from the Wellcome Trust to support its BMI1 ...
... (NASDAQ: HSKA ), a provider of ... announced that Robert Grieve, Heska,s Chairman and CEO, will present ... at 3:20 p.m. ET on Monday, January 9, 2012 in ... Hotel.  Heska management will be available during the day for ...
Cached Medicine Technology:PTC Therapeutics' Antibacterial Program Receives $5 Million Award from the Wellcome Trust 2Heska to Present at the Sidoti & Company, LLC Semi-Annual New York Micro-Cap Conference 2
(Date:12/22/2014)... In recognition of Veteran’s Day, Discount Labels ... a local organization that provides services to veterans and ... on a couple hundred acres in the hills of ... class fishing, hunting, hiking, horseback riding, 4-wheeling, skeet shooting, ... ago to support U.S. Service men and women, police ...
(Date:12/22/2014)... 2014 7,178 small business owners and ... Friday shopping and opted instead to join Digital Marketer, ... for their 5th annual “Black Friday Boot Camp”. ... to attend the 5 hour online training event and ... to support two Central Texas based charities dedicated to ...
(Date:12/22/2014)... December 22, 2014 NAPW ... Professional Woman of the Year. Ms. Foley is recognized ... the largest, most-recognized networking organization of professional women in ... National Association of Professional Women is a powerfully vibrant ... Local Chapters. , “As a nurse, I felt like ...
(Date:12/22/2014)... Washington, DC (PRWEB) December 22, 2014 ... Nursing Leadership Conference, next month in San ... strategies to address dynamics that often stand in ... authority, and competition. , This premier faculty ... Center for Transformational Leadership, whose mission is to ...
(Date:12/21/2014)... an outstanding online supplier of wedding dresses and women’s ... of Cocktail Dresses for the winter 2014. All these ... trends. , “We take pride in releasing ... of them are offered at greatly discounted rates, up ... to offer a nice shopping experience for global customers.” ...
Breaking Medicine News(10 mins):Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Michelle M. Foley, Vice President of Operations of OTTR Chronic Care Solutions, a 2014 Professional Woman of the Year 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:Stunning Cocktail Party Dresses from Weddingshe.com 2
... , MONDAY, Feb. 27 (HealthDay News) -- Rapid diagnostic ... flu season could lead to earlier treatment for patients and ... suggest. The 2012 flu season is just beginning and, ... 5 million people worldwide, experts say. Most patients will recover, ...
... news digest: , Summary of a study being ... Clinical Oncology , showing that women who underwent a once-common ... slightly lower on cognitive tests that measure word learning, memory ... cancer. While CMF is no longer the standard ...
... MONDAY, Feb. 27 (HealthDay News) -- If a luxurious-looking car ... That,s the message of a new observational study that contends ... cut off pedestrians and ignore stop-sign etiquette. The new ... experiments done by the researchers found that study participants ...
... By Jenifer Goodwin HealthDay Reporter , SUNDAY, Feb. ... cells from adult human ovaries that can mature into eggs ... which upend longstanding scientific theory, could potentially lead to ... woman,s fertility. It was long believed that women were ...
... -- A second company has issued a voluntary recall of ... lead to incorrect dosing and expose women to unintended pregnancies. ... control pill packets, sold as Norgestimate and Ethinyl Estradiol, do ... these oral contraceptives should immediately switch to another form of ...
... TAK-875, a new treatment for type 2 diabetes, improves blood ... a significantly lower risk of creating a dangerous drop in ... The results of the phase 2 randomized trial were published ... 2 diabetes is the most common form of diabetes accounting ...
Cached Medicine News:Health News:Rapid Flu Tests a Good First Step: Study 2Health News:First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen 2Health News:First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen 3Health News:First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen 4Health News:Are the Rich Really Different From You and Me? 2Health News:Are the Rich Really Different From You and Me? 3Health News:Stem Cell Finding Could Expand Women's Lifetime Supply of Eggs 2Health News:Stem Cell Finding Could Expand Women's Lifetime Supply of Eggs 3Health News:Another Batch of Birth Control Pills Recalled for Faulty Packaging 2Health News:Another Batch of Birth Control Pills Recalled for Faulty Packaging 3Health News:Diabetes drug gets patients with Type 2 diabetes on target 2
... The FR-120F, Fujinon's new fiberoptic Naso-Pharyngo-Laryngoscope ... and patient comfort. The latest in ... an increased light guide, and a wide ... very impressive 3.3mm distal tip diameter. ...
... Tip Laryngoscopes are the most ... The articulating tip aids during ... improved view of epiglottis. Available ... styles. We guarantee your complete ...
German Style MacIntosh Fiber Optic Blade Laryngoscopes...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
Medicine Products: